Literature DB >> 1731020

Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection.

R Garofalo1, J L Kimpen, R C Welliver, P L Ogra.   

Abstract

Eosinophil cationic protein (ECP), a cytotoxic protein contained in the granules of eosinophils, has been suggested as having an important role in the pathogenesis of asthma. To determine whether ECP plays a similar role in bronchiolitis, we tested samples of nasopharyngeal secretions, obtained from a group of 47 children with various forms of illness related to respiratory syncytial virus (RSV) and from 26 children with non-RSV upper respiratory tract illness or bacterial pneumonia, for the presence of ECP by means of a double-antibody radioimmunoassay. Concentrations of ECP in children with RSV bronchiolitis were significantly higher (166.8 ng/ml) than the mean concentration of ECP in both groups of children with RSV upper respiratory tract illness (43.5 ng/ml, p less than 0.002) and RSV lower respiratory tract disease without wheezing (29.1 ng/ml; p less than 0.0002). Children with non-RSV upper respiratory tract illness or bacterial pneumonia had levels of ECP in nasopharyngeal secretions similar to those of children with RSV upper respiratory tract illness or RSV pneumonia. High ECP levels in nasopharyngeal secretions (greater than 50 ng/ml) were predictive of the development of bronchiolitis at the time of RSV infection (p less than 0.001), and the individual ECP levels correlated with severity of the disease as determined by the initial PaO2 concentrations (p less than 0.05). These data suggest that eosinophil degranulation in the respiratory tract occurs during RSV bronchiolitis and may play a significant role in the development of virus-induced airway obstruction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731020     DOI: 10.1016/s0022-3476(05)80592-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  64 in total

1.  Immunological responses to respiratory syncytial virus infection in infancy.

Authors:  R L Smyth; J N Fletcher; H M Thomas; C A Hart
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  The use of the nose to study the inflammatory response of the respiratory tract.

Authors:  C G Persson; C Svensson; L Greiff; M Anderson; P Wollmer; U Alkner; I Erjefält
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

3.  Development of original donor cell leukemia after successful engraftment from a second donor.

Authors:  Jane M Stevens; Denise Syndercombe-Court; Heather E Oakervee; Daniel McCloskey; Michael J Jenner; John G Gribben; Jamie D Cavenagh
Journal:  Blood       Date:  2007-12-15       Impact factor: 22.113

Review 4.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 5.  Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses.

Authors:  P Andersen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

Review 6.  Why do viruses make infants wheeze?

Authors:  I M Balfour-Lynn
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

Review 7.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 8.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

9.  Viral respiratory infection and the link to asthma.

Authors:  James E Gern
Journal:  Pediatr Infect Dis J       Date:  2008-10       Impact factor: 2.129

Review 10.  Eosinophil-derived neurotoxin / RNase 2: connecting the past, the present and the future.

Authors:  H F Rosenberg
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.